Anebulo Pharmaceuticals (ANEB) announced the first subjects dosed in its Phase 1 single ascending dose study of intravenous selonabant in healthy young adults. The study is supported by a collaborative grant from the National Institute on Drug Abuse.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANEB: